drugset / Trial / NCT07344818
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
Phase 0
Recruiting
18 enrolled
Peking University People's Hospital
Hebei Senlang Biotechnology Inc., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To observe the efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory or relapsed aggressive B-cell lymphoma
Timeline
- Start
- 2026-01-07
- Primary completion
- 2027-03-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19+CD20 dual CAR-T cells | Cell therapy | 2e+06 cells/kg | — |
| Subject | CD19+CD20 dual CAR-T cells | Cell therapy | 4e+06 cells/kg | — |
| Subject | CD19+CD20 dual CAR-T cells | Cell therapy | 6e+06 cells/kg | — |